loading page

Manuscript title Prospective evaluation of oral levetiracetam for prophylaxis of busulfan-induced seizures in children undergoing hematopoietic stem cell transplantation
  • +4
  • Marcelo de Melo Aragão,
  • Gustavo Zamperlini,
  • Adriana Seber,
  • Zecchin VG,
  • Cintia Monteiro Lustosa,
  • Ricardo Pinho,
  • Marcelo Rodrigues
Marcelo de Melo Aragão
Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC

Corresponding Author:aragao@unifesp.br

Author Profile
Gustavo Zamperlini
Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC
Author Profile
Adriana Seber
Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC
Author Profile
Zecchin VG
Hospital Beneficencia Portuguesa de Sao Paulo
Author Profile
Cintia Monteiro Lustosa
Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC
Author Profile
Ricardo Pinho
Pediatric Oncology Institute Grupo de Apoio ao Adolescente e à Criança com Câncer (GRAACC
Author Profile
Marcelo Rodrigues
Instituto de Neurociência do Espírito Santo
Author Profile

Abstract

Busulfan is commonly used in the conditioning regimen for hematopoietic stem cell transplantation. Due to the risk of seizures associated with its use, prophylaxis with an anti-seizure drug is required. We prospectively evaluated the effectiveness of oral levetiracetam in children and adolescents for the prevention of busulfan-induced seizures. None of the 64 patients included in the study experienced seizures during the conditioning therapy or side effects that required discontinuation of the drug. Our results suggest that oral levetiracetam is effective in this setting.
10 Aug 2023Submitted to Cancer Reports
11 Aug 2023Assigned to Editor
11 Aug 2023Submission Checks Completed
11 Aug 2023Review(s) Completed, Editorial Evaluation Pending
18 Aug 2023Reviewer(s) Assigned
26 Sep 2023Editorial Decision: Revise Major